Skip to main content
. Author manuscript; available in PMC: 2016 Dec 1.
Published in final edited form as: Clin Exp Metastasis. 2015 Oct 7;32(8):799–817. doi: 10.1007/s10585-015-9752-z

Fig. 2. Dose-response, pharmacokinetics (PK), and pharmacodynamics (PD) of OXA-11 inhibition of pFAK [Y397].

Fig. 2

a Higher baseline tumor cell pFAK [Y397] was predictive of greater response to OXA-11 in eight ovarian cancer cell lines. Four tumor cell lines with the highest pFAK [Y397] levels had the lowest EC50 for OXA-11 inhibition of proliferation in vitro. b OXA-11 inhibition of TOV21G tumor growth over the dosage range of 20–120 mg/kg daily for 3 weeks. c, d PK/PD analysis of OXA-11 inhibition of pFAK [Y397] in TOV21G tumors in mice after one 80-mg/kg dose (c). Comparison of plasma exposure and inhibition of pFAK [Y397] at 4, 8, and 24 h after one OXA-11 dose of 80 or 120 mg/kg (d). e OXA-11 PD in MDA-MB-361 breast tumors in mice reflected by inhibition of pFAK [Y397] over 24 h after one dose of 40 or 120 mg/kg (n = 8 mice/group). OXA-11 inhibited MDA-MB-361 tumor growth over 3 weeks by 60 % at the lower daily dose and 95 % at the higher dose (data not shown)